| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 05-13-2024 | 03-31-2024 | 10-Q |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Leerink Partners analyst Michael Cherny initiates coverage on Boundless Bio (NASDAQ:BOLD) with a Outperform rating and annou...
Guggenheim analyst Yige Guo initiates coverage on Boundless Bio (NASDAQ:BOLD) with a Buy rating and announces Price Target o...
Piper Sandler analyst Joseph Catanzaro initiates coverage on Boundless Bio (NASDAQ:BOLD) with a Overweight rating and announ...
Findings support the ongoing development of BBI-355, a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1) in Phase ...
The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are ...
With the start of a new week comes the excitement surrounding a new set of companies looking to make an impact through their pu...
